Sartorius’ $100m Puerto Rico expansion enables greater supply for US industry

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/dennisvdw)
(Image: Getty/dennisvdw)

Related tags: Sartorius, Puerto rico, Supply and demand, downstream systems, processing, equipment, Single-use technology, Single-use systems, Manufacturing

Sartorius’ investment in Puerto Rico site doubles production capacity of manufacturing equipment for the biopharmaceutical industry.

The $100m (€89.2m) investment at the Yauco, Puerto Rico, facility doubled the production capacity of membrane filters and single-use bags for biopharmaceutical manufacture, most of which are supplied to the US.

Joachim Kreuzburg, CEO and executive board chairman of Sartorius, said in a statement, “Operationally and strategically, this expansion is an important investment for us. The considerably higher production capacities created as a result now give us leeway to deliver an even wider product array directly from the region to our American customers and to implement our ambitious growth plans in the Americas.”

After three years of construction, the factory site is 2m-square-feet and is designed to enable additional growth in the long-term, as Sartorius can double its manufacturing capabilities once more if needed.

Sartorius opened its facility in Yauco and has been manufacturing filter membranes there since 1982, adding the production of sterile single-use bags in 2012. The facility currently employees more than 500 people.

According to this was the first time Sartorius added production capacity for manufacturing filter membranes outside of its headquarters in Göttingen, Germany.

The company currently has 60 manufacturing and sales sites across the globe, employing 8,500 people. Sartorius reported global revenue of $1.68bn in FY18 results.

In March 2019, Sartorius and Novasep​ collaborated to introduce new membrane technology and single -use solutions into the company’s applications. In doing so, the partnership saw Sartorius supply products for both upstream and downstream processing equipment.

Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers

Follow us

Products

View more

Webinars